Skip to main content

Recent Developments in the Synthesis of Nicotinic Acetylcholine Receptor Ligands

Buy Article:

$55.00 plus tax (Refund Policy)

The extraordinary pharmacology of nicotine and epibatidine have indicated the potential for nicotinic acetylcholine receptor (nAChR) ligands to serve as a new therapeutic class for a host of CNS disorders. Many such ligands are natural products, or analogs thereof, which represent a significant challenge to the synthetic chemist. Synthesis of such molecules often serves as a showcase to demonstrate the potential of newly developed methodology. This synthetic challenge coupled with the promise of pharmacological activity in compounds possessing the nicotinic pharmacophore has stimulated a great deal of synthetic activity over the last five years. The present report provides an overview of novel synthetic methodology occurring during this period directed toward the synthesis of compounds with presumed affinity for the neuronal nAChR. Syntheses chosen for review here represent the major efforts toward molecules such as epibatidine analogs, anatoxin-a, nicotine and related alkaloids, conformationally constrained nicotine derivatives, cytisine and methyllycaconitine (MLA).
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Nicotinic Acetylcholine Receptor; alkaloids; methyllycaconitine (MLA); neuronal nAChR; pharmacophore

Document Type: Review Article

Affiliations: Medicinal Chemistry, Targacept, Inc., 200 East First St., Suite 300, Winston-Salem, NC 27101, USA.

Publication date: 2004-02-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more